Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2013 Jordan Sarver	Pathology in the Era of Personalized Medicine With their knowledge of molecular genetics, Pathologists are transforming the way healthcare is provided.
Pharmaceutical Executive March 1, 2011 Jerry Coamey	Engage the Physician! New research shows that gauging the mind of the clinician is crucial to timely uptake of the new diagnostic tools offered by the genomic revolution
Pharmaceutical Executive September 1, 2011 Don Creighton	Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement.
Bio-IT World February 18, 2004	Pathology Goes Molecular New technologies are enabling clinical diagnostic laboratories to pave the way toward more personalized cancer therapies
Pharmaceutical Executive September 1, 2005 Mattingly & Saxberg	Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Pharmaceutical Executive October 1, 2008	Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
The Motley Fool August 24, 2007 Brian Orelli	Take Your Medicine; Earn Your Profits Personalized medicine offers investment ideas. Let's take a look at what this new catchphrase in the medical community actually means, and how investors can benefit from it.
Bio-IT World March 2007 Michael A. Greeley	Can I Get Personal? VC's are back and seem very excited about the broader disease management and personalized medicine investment opportunities.
Bio-IT World March 2006 Michael A. Greeley	The Theranostics Promise A huge amount of discovery and clinical development for new drugs involves clinical trials that include companion diagnostic tests. These theranostic tests are poised to become a promising market for entrepreneurs, though challenges -- such as patent issues -- remain.
Bio-IT World November 14, 2003 Kathy Ordonez	Targeted Medicine via Molecular Diagnostics Using diagnostics to select and deselect target populations for drug therapy will enable life scientists to make more effective medicines.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
The Motley Fool August 29, 2011 Brian Orelli	Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive.
Pharmaceutical Executive June 1, 2006 Nancy Dreyer	Personalized Medicine Meets the Real World A wave of genomic medicines is coming down the pipeline, and they're going to be expensive. Can companies prove they're worth it? Maybe: but the claims payers seek aren't coming from traditional clinical trials.
BusinessWeek September 5, 2005	Putting the FDA Out Front Deputy Commissioner Dr. Janet Woodcock explains how the agency has led the drive for personalized medicine.
Pharmaceutical Executive January 1, 2009 Amit Agarwal	Overlooked Opportunities For pharma companies facing a difficult economic climate, pairing diagnostics with therapies offers a powerful incentive: Manufacturers can improve sales by helping physicians find the most appropriate therapeutic option.
The Motley Fool October 27, 2010 Ralph Casale	Companion Diagnostics in Cancer Drug Development Diagnostic companies partnering with drug developers can make for an attractive investment segment.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
Bio-IT World August 13, 2003 Malorye Branca	Targeting Tumors Next-generation cancer drugs will take aim with unprecedented certainty, but making them requires a new discovery and development paradigm.
The Motley Fool September 18, 2007 Brian Orelli	Another Partnership for Personalized Medicine Celera gets a contract to design a companion diagnostic test for Merck. Investors, take note.
Managed Care February 2008 Thomas Morrow	As the Use of Biomarkers Grows, Managed Care Companies Will Face Tough Decisions About Setting Limits Health care faces difficult challenges as it increasingly incorporates a personalized approach that uses various biomarkers to influence medical decision-making.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
Pharmaceutical Executive July 1, 2011 William Looney	Planning Beyond the Petri Dish Pfizer's crizotinib development program combined organization, art, and science, and a large dose of unforeseen risk.
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
Wired July 2006 Kevin Kelleher	Personalize It While Adidas offers customized shoes for your feet, the pharmaceutical industry is moving toward personalizing drugs based on your genes.
Bio-IT World December 15, 2003 Kevin Davies	The Road to Personalized Medicine FDA guidance on the road to genomic medicine is a welcome first step in what promises to be a contentious debate on how to integrate pharmacogenomics into routine medical practice.
Scientific American March 2009 Elaine Schattner	A Chip against Cancer: Microfluidics Scrutinizes T Cells With just a blood sample, a device could determine whether cancer is about to spread or monitor the progress of treatment
Bio-IT World September 9, 2002 Malorye Branca	The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems.
Managed Care November 2004 Thomas Morrow	Pharmacogenetic, Pharmacogenomic Testing Rapidly Gaining Acceptance New tests will allow better determination of which therapies will work on which patients, thus improving care and reducing outlays for failed therapies.
Pharmaceutical Executive September 1, 2010	The Testing of the Tests FDA seeks to regulate genetic tests more actively, while encouraging diagnostic development.
Pharmaceutical Executive September 1, 2012 Stan Bernard	The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model.
Bio-IT World February 11, 2005 Robert M. Frederickson	Genomics Drives New Crop of IVDs In vitro diagnostic microarrays are an important tool in oncology. The Affymetrix GeneChip System 3000Dx (GCS 3000Dx) was the first microarray instrument to be cleared by the FDA for IVD use.
Pharmaceutical Executive July 1, 2012 Jill Wechsler	Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies.
The Motley Fool February 4, 2011 Brian Orelli	Glaxo Sold Quest Shares. Should You? Glaxo has somewhere else to spend the capital. Do you?
Chemistry World June 9, 2015 Phillip Broadwith	Opko deepens diagnostics with $1.5bn lab buyout Healthcare firm Opko is aiming to enhance its position in diagnostic technology by agreeing to buy clinical diagnostics service BioReference Laboratories.
BusinessWeek September 5, 2005 Capell & Arndt	Drugs Get Smart Future medicines will more effectively target what ails you by tailoring treatment to your specific genetic profile. Personalized medicine will also help prevent another Vioxx.
The Motley Fool June 20, 2008 Brian Orelli	Live From Bio: Personalized Medicine The movement is chugging along thanks to diagnostics.
BusinessWeek October 1, 2007 Conrad Wilson	A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution.
Pharmaceutical Executive August 1, 2014 Ben Comer	Pharm Exec's 2014 Emerging Pharma Leaders This year's class of 15 young executives is deeply of the moment, with wide-ranging therapeutic, business, and operational expertise.
Pharmaceutical Executive August 1, 2012 Debbie Warner	Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.
Pharmaceutical Executive May 1, 2007 Patrick Clinton	The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought.
Bio-IT World April 16, 2004	Portraits in Proteomics Advances in identifying protein biomarkers are spurring new hope in cancer diagnostics, expediting detection and easing testing.
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann	Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact.
The Motley Fool July 14, 2009 Brian Orelli	Diagnosing a Personalized Partnership Abbott and Glaxo hook up on diagnostics.
Pharmaceutical Executive August 1, 2012	Sunny Outlook for Biopharm 2020? Albert Wertheimer looks beyond today's dark clouds with a comparatively sunny forecast for the biopharm industry in 2020. Just watch out for the harsh light of complacency.
Pharmaceutical Executive November 1, 2013	Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation.
Managed Care May 2004 Thomas Morrow	New Agents Regulating Tyrosine Kinase Can Be Used Against Several Cancers When traditional therapies fail in cancer treatment, turning off a chemical switch may offer hope to the hopeless.